Figure 2From: A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejectionEffect of concentrations of [125I]hCXCL10 and [125I]hCXCL11 on the IC 50 of SCH 546738 binding to human CXCR3 receptor. The ability of SCH 546738 to compete the binding of [125I]hCXCL10 and [125I]hCXCL11 to human CXCR3 receptor was determined using various concentrations of [125I]hCXCL10 and [125I]hCXCL11 as described in Methods. After 3 hr reaction, specific counts relative to input counts (B/B0) in the presence of increasing concentrations of SCH 546738 are plotted. The IC50 for each concentration of [125I]hCXCL10 and [125I]hCXCL11 are shown.Back to article page